Summary
Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on October 23, 2019, to report its financial results for the third quarter ended September 30, 2019. The filing primarily includes a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance during the period. While specific financial figures are not detailed within the 8-K's text itself, the furnished press release serves as the core informational document for evaluating the company's operational and financial standing. Investors should note that the information furnished in this 8-K is not considered 'filed' for Section 18 purposes and is not automatically incorporated into future SEC filings unless specifically referenced. The report also contains standard forward-looking statements that caution readers about the inherent risks and uncertainties in predicting future performance, including regulatory changes, healthcare cost trends, competitive pressures, and potential litigation. These disclaimers are important for contextualizing the reported results and forward-looking guidance.
Key Highlights
- 1The 8-K filing from October 23, 2019, serves to officially report Elevance Health's (then Anthem, Inc.) third-quarter financial results for the period ending September 30, 2019.
- 2The primary content of the filing is a press release (Exhibit 99.1) containing the detailed financial results and operational updates for the quarter.
- 3Information furnished in this 8-K is explicitly stated as not 'filed' for Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same legal implications as formally filed information.
- 4The document includes standard 'forward-looking statements' advising investors to be aware of potential risks and uncertainties that could impact future financial performance.
- 5Key risk factors mentioned include regulatory impacts (especially the ACA), healthcare cost trends, provider contracting, premium rate approvals, competitive landscape, and enrollment trends.
- 6Significant potential risks also encompass litigation, government investigations, compliance with Medicare and Medicaid programs, quality ratings (CMS Star Ratings), changes in product mix, and pharmacy benefit management (PBM) agreement-related issues.
- 7The company highlights potential liabilities and disruptions stemming from litigation with Cigna Corporation and issues related to PBM service transitions with Express Scripts and CVS Health.